CXCR1 and cancer: In these experiments, rather than using siRNA to deplete CXCR1/2 signalling potential, we employed CXCR1/2-targeted peptidomimetics termed ‘pepducins’ that have been shown to uncouple the receptors from activating the intrinsic G proteins, blocking signal transduction in both in vitro and in vivo cancer models (27).